Robert J Griffin (Robert Griffin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Advanced Non Small Cell Lung Cancer

Top Venues

Investigational new drugs

Proceedings of the National Academy of Sciences of the United States of America

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs (2024)
Neeraj Gupta, Michael J Hanley, Robert J Griffin, Pingkuan Zhang, Karthik Venkatakrishnan, Vikram Sinha
Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clinical pharmacokinetics (2023)
Stanley C Xie, Riley D Metcalfe, Hirotake Mizutani, Tanya Puhalovich, Eric Hanssen, Craig J Morton, Yawei Du, Con Dogovski, Shih-Chung Huang, Jeffrey Ciavarri, Paul Hales, Robert J Griffin, Lawrence H Cohen, Bei-Ching Chuang, Sergio Wittlin, Ioanna Deni, Tomas Yeo, Kurt E Ward, Daniel C Barry, Boyin Liu, David L Gillett, Benigno F Crespo-Fernandez, Sabine Ottilie, Nimisha Mittal, Alisje Churchyard, Daniel Ferguson, Anna Caroline Campos Aguiar, Rafael Victorio Carvalho Guido, Jake Baum, Kirsten K Hanson, Elizabeth A Winzeler, Francisco Javier Gamo, David A Fidock, Delphine Baud, Michael W Parker, Stephen Brand, Lawrence R Dick, Michael D W Griffin, Alexandra E Gould, Leann Tilley
Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America 118 (39) (2021)